Botulinum Toxin Market By Product (Botulinum Toxin Type A, Botulinum Toxin Type B), By Application (Aesthetic, Therapeutic), By End User (Hospitals, Specialty and Dermatology Clinics, Others): Global Opportunity Analysis and Industry Forecast, 2021-2031
Description
Botulinum Toxin Market By Product (Botulinum Toxin Type A, Botulinum Toxin Type B), By Application (Aesthetic, Therapeutic), By End User (Hospitals, Specialty and Dermatology Clinics, Others): Global Opportunity Analysis and Industry Forecast, 2021-2031
The global Botulinum toxin market accounted for $5814.9 million in 2021, and is expected to reach $13132.72 million by 2031, registering a CAGR of 8.6% from 2022 to 2031.
Botulinum toxin, one of the most poisonous biological substances known, and is a neurotoxin produced by the bacterium Clostridium botulinum. C. Botulinum elaborates eight antigenically distinguishable exotoxins (A, B, C1, C2, D, E, F and G). All serotypes interfere with neural transmission by blocking the release of acetylcholine, the principal neurotransmitter at the neuromuscular junction, causing muscle paralysis. The weakness induced by injection with botulinum toxin A usually lasts about three months.
Botulinum toxins now play a significant role in the management of a wide variety of medical conditions, especially strabismus and focal dystonia and some chronic conditions that respond only partially to medical treatment. The list of possible new indications is rapidly expanding. The aesthetic applications include correction of lines, creases and wrinkling all over the face, chin, neck, and chest to dermatological applications such as hyperhidrosis. Injections with botulinum toxin are generally well tolerated and side effects are few. A precise knowledge and understanding of the functional anatomy of the mimetic muscles is necessary to correctly use botulinum toxins in clinical practice.
The botulinum toxin market is expected to experience significant growth during the forecast period owing to surge in demand for cosmetic non-invasive surgical procedures, new product launches, increase in affordability and amendments in reimbursement policies to cover botulinum injections. In addition, rise in number of botulinum toxin procedure further facilitates the growth of the market. However, side effects associated with Botox procedures and high cost of these procedures are expected to impede the market growth in emerging region. In contrast, rise in investment in R&D activities by major manufacturers to explore the therapeutic use of botulinum toxin are anticipated to provide significant growth opportunities for the botulinum toxin market.
The Botulinum toxin market is segmented on the basis of product, application, end user and region. On the basis of product, the market is classified into botulinum toxin type A and botulinum toxin type B. On the basis of application, the market is divided into aesthetic and therapeutic. On the basis of end user, the market is classified into hospitals, specialty & dermatology clinics and others.
Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
The report provides a comprehensive analysis of the key players that operate in the global botulinum toxin market. The key companies profiled in the report include Merz Pharma GmbH And Co. Kgaa, Abbvie Inc (Allergan), Ipsen Group, Revance Therapeutics Inc, Medy-Tox, Inc., Hugel, Inc., Galderma, Us Worldmed, Llc ,Evolus Inc., and Daewoong Pharmaceutical.
Key Benefits For Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the botulinum toxin market analysis from 2021 to 2031 to identify the prevailing botulinum toxin market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the botulinum toxin market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global botulinum toxin market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Application
Aesthetic
Therapeutic
By Product
Botulinum Toxin Type A
Botulinum Toxin Type B
By End User
Hospitals
Specialty and Dermatology Clinics
Others
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
Key Market Players
REVANCE THERAPEUTICS INC
Medy-Tox, Inc.
GALDERMA
US WORLDMED, LLC
Abbvie Inc (Allergan)
DAEWOONG PHARMACEUTICAL
Ipsen Group
MERZ PHARMA GMBH AND CO. KGAA
HUGEL, INC.
EVOLUS INC.
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
The global Botulinum toxin market accounted for $5814.9 million in 2021, and is expected to reach $13132.72 million by 2031, registering a CAGR of 8.6% from 2022 to 2031.
Botulinum toxin, one of the most poisonous biological substances known, and is a neurotoxin produced by the bacterium Clostridium botulinum. C. Botulinum elaborates eight antigenically distinguishable exotoxins (A, B, C1, C2, D, E, F and G). All serotypes interfere with neural transmission by blocking the release of acetylcholine, the principal neurotransmitter at the neuromuscular junction, causing muscle paralysis. The weakness induced by injection with botulinum toxin A usually lasts about three months.
Botulinum toxins now play a significant role in the management of a wide variety of medical conditions, especially strabismus and focal dystonia and some chronic conditions that respond only partially to medical treatment. The list of possible new indications is rapidly expanding. The aesthetic applications include correction of lines, creases and wrinkling all over the face, chin, neck, and chest to dermatological applications such as hyperhidrosis. Injections with botulinum toxin are generally well tolerated and side effects are few. A precise knowledge and understanding of the functional anatomy of the mimetic muscles is necessary to correctly use botulinum toxins in clinical practice.
The botulinum toxin market is expected to experience significant growth during the forecast period owing to surge in demand for cosmetic non-invasive surgical procedures, new product launches, increase in affordability and amendments in reimbursement policies to cover botulinum injections. In addition, rise in number of botulinum toxin procedure further facilitates the growth of the market. However, side effects associated with Botox procedures and high cost of these procedures are expected to impede the market growth in emerging region. In contrast, rise in investment in R&D activities by major manufacturers to explore the therapeutic use of botulinum toxin are anticipated to provide significant growth opportunities for the botulinum toxin market.
The Botulinum toxin market is segmented on the basis of product, application, end user and region. On the basis of product, the market is classified into botulinum toxin type A and botulinum toxin type B. On the basis of application, the market is divided into aesthetic and therapeutic. On the basis of end user, the market is classified into hospitals, specialty & dermatology clinics and others.
Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
The report provides a comprehensive analysis of the key players that operate in the global botulinum toxin market. The key companies profiled in the report include Merz Pharma GmbH And Co. Kgaa, Abbvie Inc (Allergan), Ipsen Group, Revance Therapeutics Inc, Medy-Tox, Inc., Hugel, Inc., Galderma, Us Worldmed, Llc ,Evolus Inc., and Daewoong Pharmaceutical.
Key Benefits For Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the botulinum toxin market analysis from 2021 to 2031 to identify the prevailing botulinum toxin market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the botulinum toxin market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global botulinum toxin market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Application
Aesthetic
Therapeutic
By Product
Botulinum Toxin Type A
Botulinum Toxin Type B
By End User
Hospitals
Specialty and Dermatology Clinics
Others
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
Key Market Players
REVANCE THERAPEUTICS INC
Medy-Tox, Inc.
GALDERMA
US WORLDMED, LLC
Abbvie Inc (Allergan)
DAEWOONG PHARMACEUTICAL
Ipsen Group
MERZ PHARMA GMBH AND CO. KGAA
HUGEL, INC.
EVOLUS INC.
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
Table of Contents
215 Pages
- CHAPTER 1:INTRODUCTION
- 1.1.Report description
- 1.2.Key market segments
- 1.3.Key benefits to the stakeholders
- 1.4.Research Methodology
- 1.4.1.Secondary research
- 1.4.2.Primary research
- 1.4.3.Analyst tools and models
- CHAPTER 2:EXECUTIVE SUMMARY
- 2.1.Key findings of the study
- 2.2.CXO Perspective
- CHAPTER 3:MARKET OVERVIEW
- 3.1.Market definition and scope
- 3.2.Key findings
- 3.2.1.Top investment pockets
- 3.3.Porter’s five forces analysis
- 3.4.Top player positioning
- 3.5.Market dynamics
- 3.5.1.Drivers
- 3.5.2.Restraints
- 3.5.3.Opportunities
- 3.6.COVID-19 Impact Analysis on the market
- CHAPTER 4: BOTULINUM TOXIN MARKET, BY PRODUCT
- 4.1 Overview
- 4.1.1 Market size and forecast
- 4.2 Botulinum Toxin Type A
- 4.2.1 Key market trends, growth factors and opportunities
- 4.2.2 Market size and forecast, by region
- 4.2.3 Market share analysis by country
- 4.3 Botulinum Toxin Type B
- 4.3.1 Key market trends, growth factors and opportunities
- 4.3.2 Market size and forecast, by region
- 4.3.3 Market share analysis by country
- CHAPTER 5: BOTULINUM TOXIN MARKET, BY APPLICATION
- 5.1 Overview
- 5.1.1 Market size and forecast
- 5.2 Aesthetic
- 5.2.1 Key market trends, growth factors and opportunities
- 5.2.2 Market size and forecast, by region
- 5.2.3 Market share analysis by country
- 5.3 Therapeutic
- 5.3.1 Key market trends, growth factors and opportunities
- 5.3.2 Market size and forecast, by region
- 5.3.3 Market share analysis by country
- CHAPTER 6: BOTULINUM TOXIN MARKET, BY END USER
- 6.1 Overview
- 6.1.1 Market size and forecast
- 6.2 Hospitals
- 6.2.1 Key market trends, growth factors and opportunities
- 6.2.2 Market size and forecast, by region
- 6.2.3 Market share analysis by country
- 6.3 Specialty and Dermatology Clinics
- 6.3.1 Key market trends, growth factors and opportunities
- 6.3.2 Market size and forecast, by region
- 6.3.3 Market share analysis by country
- 6.4 Others
- 6.4.1 Key market trends, growth factors and opportunities
- 6.4.2 Market size and forecast, by region
- 6.4.3 Market share analysis by country
- CHAPTER 7: BOTULINUM TOXIN MARKET, BY REGION
- 7.1 Overview
- 7.1.1 Market size and forecast
- 7.2 North America
- 7.2.1 Key trends and opportunities
- 7.2.2 North America Market size and forecast, by Product
- 7.2.3 North America Market size and forecast, by Application
- 7.2.4 North America Market size and forecast, by End User
- 7.2.5 North America Market size and forecast, by country
- 7.2.5.1 U.S.
- 7.2.5.1.1 Key market trends, growth factors and opportunities
- 7.2.5.1.2 Market size and forecast, by Product
- 7.2.5.1.3 Market size and forecast, by Application
- 7.2.5.1.4 Market size and forecast, by End User
- 7.2.5.2 Canada
- 7.2.5.2.1 Key market trends, growth factors and opportunities
- 7.2.5.2.2 Market size and forecast, by Product
- 7.2.5.2.3 Market size and forecast, by Application
- 7.2.5.2.4 Market size and forecast, by End User
- 7.2.5.3 Mexico
- 7.2.5.3.1 Key market trends, growth factors and opportunities
- 7.2.5.3.2 Market size and forecast, by Product
- 7.2.5.3.3 Market size and forecast, by Application
- 7.2.5.3.4 Market size and forecast, by End User
- 7.3 Europe
- 7.3.1 Key trends and opportunities
- 7.3.2 Europe Market size and forecast, by Product
- 7.3.3 Europe Market size and forecast, by Application
- 7.3.4 Europe Market size and forecast, by End User
- 7.3.5 Europe Market size and forecast, by country
- 7.3.5.1 Germany
- 7.3.5.1.1 Key market trends, growth factors and opportunities
- 7.3.5.1.2 Market size and forecast, by Product
- 7.3.5.1.3 Market size and forecast, by Application
- 7.3.5.1.4 Market size and forecast, by End User
- 7.3.5.2 France
- 7.3.5.2.1 Key market trends, growth factors and opportunities
- 7.3.5.2.2 Market size and forecast, by Product
- 7.3.5.2.3 Market size and forecast, by Application
- 7.3.5.2.4 Market size and forecast, by End User
- 7.3.5.3 UK
- 7.3.5.3.1 Key market trends, growth factors and opportunities
- 7.3.5.3.2 Market size and forecast, by Product
- 7.3.5.3.3 Market size and forecast, by Application
- 7.3.5.3.4 Market size and forecast, by End User
- 7.3.5.4 Italy
- 7.3.5.4.1 Key market trends, growth factors and opportunities
- 7.3.5.4.2 Market size and forecast, by Product
- 7.3.5.4.3 Market size and forecast, by Application
- 7.3.5.4.4 Market size and forecast, by End User
- 7.3.5.5 Spain
- 7.3.5.5.1 Key market trends, growth factors and opportunities
- 7.3.5.5.2 Market size and forecast, by Product
- 7.3.5.5.3 Market size and forecast, by Application
- 7.3.5.5.4 Market size and forecast, by End User
- 7.3.5.6 Rest of Europe
- 7.3.5.6.1 Key market trends, growth factors and opportunities
- 7.3.5.6.2 Market size and forecast, by Product
- 7.3.5.6.3 Market size and forecast, by Application
- 7.3.5.6.4 Market size and forecast, by End User
- 7.4 Asia-Pacific
- 7.4.1 Key trends and opportunities
- 7.4.2 Asia-Pacific Market size and forecast, by Product
- 7.4.3 Asia-Pacific Market size and forecast, by Application
- 7.4.4 Asia-Pacific Market size and forecast, by End User
- 7.4.5 Asia-Pacific Market size and forecast, by country
- 7.4.5.1 Japan
- 7.4.5.1.1 Key market trends, growth factors and opportunities
- 7.4.5.1.2 Market size and forecast, by Product
- 7.4.5.1.3 Market size and forecast, by Application
- 7.4.5.1.4 Market size and forecast, by End User
- 7.4.5.2 China
- 7.4.5.2.1 Key market trends, growth factors and opportunities
- 7.4.5.2.2 Market size and forecast, by Product
- 7.4.5.2.3 Market size and forecast, by Application
- 7.4.5.2.4 Market size and forecast, by End User
- 7.4.5.3 Australia
- 7.4.5.3.1 Key market trends, growth factors and opportunities
- 7.4.5.3.2 Market size and forecast, by Product
- 7.4.5.3.3 Market size and forecast, by Application
- 7.4.5.3.4 Market size and forecast, by End User
- 7.4.5.4 India
- 7.4.5.4.1 Key market trends, growth factors and opportunities
- 7.4.5.4.2 Market size and forecast, by Product
- 7.4.5.4.3 Market size and forecast, by Application
- 7.4.5.4.4 Market size and forecast, by End User
- 7.4.5.5 South Korea
- 7.4.5.5.1 Key market trends, growth factors and opportunities
- 7.4.5.5.2 Market size and forecast, by Product
- 7.4.5.5.3 Market size and forecast, by Application
- 7.4.5.5.4 Market size and forecast, by End User
- 7.4.5.6 Rest of Asia-Pacific
- 7.4.5.6.1 Key market trends, growth factors and opportunities
- 7.4.5.6.2 Market size and forecast, by Product
- 7.4.5.6.3 Market size and forecast, by Application
- 7.4.5.6.4 Market size and forecast, by End User
- 7.5 LAMEA
- 7.5.1 Key trends and opportunities
- 7.5.2 LAMEA Market size and forecast, by Product
- 7.5.3 LAMEA Market size and forecast, by Application
- 7.5.4 LAMEA Market size and forecast, by End User
- 7.5.5 LAMEA Market size and forecast, by country
- 7.5.5.1 Brazil
- 7.5.5.1.1 Key market trends, growth factors and opportunities
- 7.5.5.1.2 Market size and forecast, by Product
- 7.5.5.1.3 Market size and forecast, by Application
- 7.5.5.1.4 Market size and forecast, by End User
- 7.5.5.2 Saudi Arabia
- 7.5.5.2.1 Key market trends, growth factors and opportunities
- 7.5.5.2.2 Market size and forecast, by Product
- 7.5.5.2.3 Market size and forecast, by Application
- 7.5.5.2.4 Market size and forecast, by End User
- 7.5.5.3 South Africa
- 7.5.5.3.1 Key market trends, growth factors and opportunities
- 7.5.5.3.2 Market size and forecast, by Product
- 7.5.5.3.3 Market size and forecast, by Application
- 7.5.5.3.4 Market size and forecast, by End User
- 7.5.5.4 Rest of LAMEA
- 7.5.5.4.1 Key market trends, growth factors and opportunities
- 7.5.5.4.2 Market size and forecast, by Product
- 7.5.5.4.3 Market size and forecast, by Application
- 7.5.5.4.4 Market size and forecast, by End User
- CHAPTER 8: COMPANY LANDSCAPE
- 8.1. Introduction
- 8.2. Top winning strategies
- 8.3. Product Mapping of Top 10 Player
- 8.4. Competitive Dashboard
- 8.5. Competitive Heatmap
- 8.6. Key developments
- CHAPTER 9: COMPANY PROFILES
- 9.1 REVANCE THERAPEUTICS INC
- 9.1.1 Company overview
- 9.1.2 Company snapshot
- 9.1.3 Operating business segments
- 9.1.4 Product portfolio
- 9.1.5 Business performance
- 9.1.6 Key strategic moves and developments
- 9.2 Medy-Tox, Inc.
- 9.2.1 Company overview
- 9.2.2 Company snapshot
- 9.2.3 Operating business segments
- 9.2.4 Product portfolio
- 9.2.5 Business performance
- 9.2.6 Key strategic moves and developments
- 9.3 galderma
- 9.3.1 Company overview
- 9.3.2 Company snapshot
- 9.3.3 Operating business segments
- 9.3.4 Product portfolio
- 9.3.5 Business performance
- 9.3.6 Key strategic moves and developments
- 9.4 US WORLDMED, LLC
- 9.4.1 Company overview
- 9.4.2 Company snapshot
- 9.4.3 Operating business segments
- 9.4.4 Product portfolio
- 9.4.5 Business performance
- 9.4.6 Key strategic moves and developments
- 9.5 Abbvie Inc (Allergan)
- 9.5.1 Company overview
- 9.5.2 Company snapshot
- 9.5.3 Operating business segments
- 9.5.4 Product portfolio
- 9.5.5 Business performance
- 9.5.6 Key strategic moves and developments
- 9.6 DAEWOONG PHARMACEUTICAL
- 9.6.1 Company overview
- 9.6.2 Company snapshot
- 9.6.3 Operating business segments
- 9.6.4 Product portfolio
- 9.6.5 Business performance
- 9.6.6 Key strategic moves and developments
- 9.7 Ipsen Group
- 9.7.1 Company overview
- 9.7.2 Company snapshot
- 9.7.3 Operating business segments
- 9.7.4 Product portfolio
- 9.7.5 Business performance
- 9.7.6 Key strategic moves and developments
- 9.8 MERZ PHARMA GMBH AND CO. KGAA
- 9.8.1 Company overview
- 9.8.2 Company snapshot
- 9.8.3 Operating business segments
- 9.8.4 Product portfolio
- 9.8.5 Business performance
- 9.8.6 Key strategic moves and developments
- 9.9 HUGEL, INC.
- 9.9.1 Company overview
- 9.9.2 Company snapshot
- 9.9.3 Operating business segments
- 9.9.4 Product portfolio
- 9.9.5 Business performance
- 9.9.6 Key strategic moves and developments
- 9.10 EVOLUS INC.
- 9.10.1 Company overview
- 9.10.2 Company snapshot
- 9.10.3 Operating business segments
- 9.10.4 Product portfolio
- 9.10.5 Business performance
- 9.10.6 Key strategic moves and developments
- LIST OF TABLES
- TABLE 1. GLOBAL BOTULINUM TOXIN MARKET, BY PRODUCT, 2021-2031 (REVENUE, $MILLION)
- TABLE 2. BOTULINUM TOXIN MARKET FOR BOTULINUM TOXIN TYPE A, BY REGION, 2021-2031 (REVENUE, $MILLION)
- TABLE 3. BOTULINUM TOXIN MARKET FOR BOTULINUM TOXIN TYPE A, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
- TABLE 4. BOTULINUM TOXIN MARKET FOR BOTULINUM TOXIN TYPE B, BY REGION, 2021-2031 (REVENUE, $MILLION)
- TABLE 5. BOTULINUM TOXIN MARKET FOR BOTULINUM TOXIN TYPE B, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
- TABLE 6. GLOBAL BOTULINUM TOXIN MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
- TABLE 7. BOTULINUM TOXIN MARKET FOR AESTHETIC, BY REGION, 2021-2031 (REVENUE, $MILLION)
- TABLE 8. BOTULINUM TOXIN MARKET FOR AESTHETIC, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
- TABLE 9. BOTULINUM TOXIN MARKET FOR THERAPEUTIC, BY REGION, 2021-2031 (REVENUE, $MILLION)
- TABLE 10. BOTULINUM TOXIN MARKET FOR THERAPEUTIC, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
- TABLE 11. GLOBAL BOTULINUM TOXIN MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
- TABLE 12. BOTULINUM TOXIN MARKET FOR HOSPITALS, BY REGION, 2021-2031 (REVENUE, $MILLION)
- TABLE 13. BOTULINUM TOXIN MARKET FOR HOSPITALS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
- TABLE 14. BOTULINUM TOXIN MARKET FOR SPECIALTY AND DERMATOLOGY CLINICS, BY REGION, 2021-2031 (REVENUE, $MILLION)
- TABLE 15. BOTULINUM TOXIN MARKET FOR SPECIALTY AND DERMATOLOGY CLINICS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
- TABLE 16. BOTULINUM TOXIN MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
- TABLE 17. BOTULINUM TOXIN MARKET FOR OTHERS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
- TABLE 18. BOTULINUM TOXIN MARKET, BY REGION, 2021-2031 (REVENUE, $MILLION)
- TABLE 19. NORTH AMERICA BOTULINUM TOXIN MARKET, BY PRODUCT, 2021-2031 (REVENUE, $MILLION)
- TABLE 20. NORTH AMERICA BOTULINUM TOXIN MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
- TABLE 21. NORTH AMERICA BOTULINUM TOXIN MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
- TABLE 22. NORTH AMERICA BOTULINUM TOXIN MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
- TABLE 23. U.S. BOTULINUM TOXIN MARKET, BY PRODUCT, 2021-2031 (REVENUE, $MILLION)
- TABLE 24. U.S. BOTULINUM TOXIN MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
- TABLE 25. U.S. BOTULINUM TOXIN MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
- TABLE 26. CANADA BOTULINUM TOXIN MARKET, BY PRODUCT, 2021-2031 (REVENUE, $MILLION)
- TABLE 27. CANADA BOTULINUM TOXIN MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
- TABLE 28. CANADA BOTULINUM TOXIN MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
- TABLE 29. MEXICO BOTULINUM TOXIN MARKET, BY PRODUCT, 2021-2031 (REVENUE, $MILLION)
- TABLE 30. MEXICO BOTULINUM TOXIN MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
- TABLE 31. MEXICO BOTULINUM TOXIN MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
- TABLE 32. EUROPE BOTULINUM TOXIN MARKET, BY PRODUCT, 2021-2031 (REVENUE, $MILLION)
- TABLE 33. EUROPE BOTULINUM TOXIN MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
- TABLE 34. EUROPE BOTULINUM TOXIN MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
- TABLE 35. EUROPE BOTULINUM TOXIN MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
- TABLE 36. GERMANY BOTULINUM TOXIN MARKET, BY PRODUCT, 2021-2031 (REVENUE, $MILLION)
- TABLE 37. GERMANY BOTULINUM TOXIN MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
- TABLE 38. GERMANY BOTULINUM TOXIN MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
- TABLE 39. FRANCE BOTULINUM TOXIN MARKET, BY PRODUCT, 2021-2031 (REVENUE, $MILLION)
- TABLE 40. FRANCE BOTULINUM TOXIN MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
- TABLE 41. FRANCE BOTULINUM TOXIN MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
- TABLE 42. UK BOTULINUM TOXIN MARKET, BY PRODUCT, 2021-2031 (REVENUE, $MILLION)
- TABLE 43. UK BOTULINUM TOXIN MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
- TABLE 44. UK BOTULINUM TOXIN MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
- TABLE 45. ITALY BOTULINUM TOXIN MARKET, BY PRODUCT, 2021-2031 (REVENUE, $MILLION)
- TABLE 46. ITALY BOTULINUM TOXIN MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
- TABLE 47. ITALY BOTULINUM TOXIN MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
- TABLE 48. SPAIN BOTULINUM TOXIN MARKET, BY PRODUCT, 2021-2031 (REVENUE, $MILLION)
- TABLE 49. SPAIN BOTULINUM TOXIN MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
- TABLE 50. SPAIN BOTULINUM TOXIN MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
- TABLE 51. REST OF EUROPE BOTULINUM TOXIN MARKET, BY PRODUCT, 2021-2031 (REVENUE, $MILLION)
- TABLE 52. REST OF EUROPE BOTULINUM TOXIN MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
- TABLE 53. REST OF EUROPE BOTULINUM TOXIN MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
- TABLE 54. ASIA-PACIFIC BOTULINUM TOXIN MARKET, BY PRODUCT, 2021-2031 (REVENUE, $MILLION)
- TABLE 55. ASIA-PACIFIC BOTULINUM TOXIN MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
- TABLE 56. ASIA-PACIFIC BOTULINUM TOXIN MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
- TABLE 57. ASIA-PACIFIC BOTULINUM TOXIN MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
- TABLE 58. JAPAN BOTULINUM TOXIN MARKET, BY PRODUCT, 2021-2031 (REVENUE, $MILLION)
- TABLE 59. JAPAN BOTULINUM TOXIN MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
- TABLE 60. JAPAN BOTULINUM TOXIN MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
- TABLE 61. CHINA BOTULINUM TOXIN MARKET, BY PRODUCT, 2021-2031 (REVENUE, $MILLION)
- TABLE 62. CHINA BOTULINUM TOXIN MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
- TABLE 63. CHINA BOTULINUM TOXIN MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
- TABLE 64. AUSTRALIA BOTULINUM TOXIN MARKET, BY PRODUCT, 2021-2031 (REVENUE, $MILLION)
- TABLE 65. AUSTRALIA BOTULINUM TOXIN MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
- TABLE 66. AUSTRALIA BOTULINUM TOXIN MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
- TABLE 67. INDIA BOTULINUM TOXIN MARKET, BY PRODUCT, 2021-2031 (REVENUE, $MILLION)
- TABLE 68. INDIA BOTULINUM TOXIN MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
- TABLE 69. INDIA BOTULINUM TOXIN MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
- TABLE 70. SOUTH KOREA BOTULINUM TOXIN MARKET, BY PRODUCT, 2021-2031 (REVENUE, $MILLION)
- TABLE 71. SOUTH KOREA BOTULINUM TOXIN MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
- TABLE 72. SOUTH KOREA BOTULINUM TOXIN MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
- TABLE 73. REST OF ASIA-PACIFIC BOTULINUM TOXIN MARKET, BY PRODUCT, 2021-2031 (REVENUE, $MILLION)
- TABLE 74. REST OF ASIA-PACIFIC BOTULINUM TOXIN MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
- TABLE 75. REST OF ASIA-PACIFIC BOTULINUM TOXIN MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
- TABLE 76. LAMEA BOTULINUM TOXIN MARKET, BY PRODUCT, 2021-2031 (REVENUE, $MILLION)
- TABLE 77. LAMEA BOTULINUM TOXIN MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
- TABLE 78. LAMEA BOTULINUM TOXIN MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
- TABLE 79. LAMEA BOTULINUM TOXIN MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
- TABLE 80. BRAZIL BOTULINUM TOXIN MARKET, BY PRODUCT, 2021-2031 (REVENUE, $MILLION)
- TABLE 81. BRAZIL BOTULINUM TOXIN MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
- TABLE 82. BRAZIL BOTULINUM TOXIN MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
- TABLE 83. SAUDI ARABIA BOTULINUM TOXIN MARKET, BY PRODUCT, 2021-2031 (REVENUE, $MILLION)
- TABLE 84. SAUDI ARABIA BOTULINUM TOXIN MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
- TABLE 85. SAUDI ARABIA BOTULINUM TOXIN MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
- TABLE 86. SOUTH AFRICA BOTULINUM TOXIN MARKET, BY PRODUCT, 2021-2031 (REVENUE, $MILLION)
- TABLE 87. SOUTH AFRICA BOTULINUM TOXIN MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
- TABLE 88. SOUTH AFRICA BOTULINUM TOXIN MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
- TABLE 89. REST OF LAMEA BOTULINUM TOXIN MARKET, BY PRODUCT, 2021-2031 (REVENUE, $MILLION)
- TABLE 90. REST OF LAMEA BOTULINUM TOXIN MARKET, BY APPLICATION, 2021-2031 (REVENUE, $MILLION)
- TABLE 91. REST OF LAMEA BOTULINUM TOXIN MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
- TABLE 92.REVANCE THERAPEUTICS INC: COMPANY SNAPSHOT
- TABLE 93.REVANCE THERAPEUTICS INC: OPERATING SEGMENTS
- TABLE 94.REVANCE THERAPEUTICS INC: PRODUCT PORTFOLIO
- TABLE 95.REVANCE THERAPEUTICS INC: NET SALES
- TABLE 96.REVANCE THERAPEUTICS INC: KEY STRATERGIES
- TABLE 97.MEDY-TOX, INC.: COMPANY SNAPSHOT
- TABLE 98.MEDY-TOX, INC.: OPERATING SEGMENTS
- TABLE 99.MEDY-TOX, INC.: PRODUCT PORTFOLIO
- TABLE 100.MEDY-TOX, INC.: NET SALES
- TABLE 101.MEDY-TOX, INC.: KEY STRATERGIES
- TABLE 102.GALDERMA: COMPANY SNAPSHOT
- TABLE 103.GALDERMA: OPERATING SEGMENTS
- TABLE 104.GALDERMA: PRODUCT PORTFOLIO
- TABLE 105.GALDERMA: NET SALES
- TABLE 106.GALDERMA: KEY STRATERGIES
- TABLE 107.US WORLDMED, LLC: COMPANY SNAPSHOT
- TABLE 108.US WORLDMED, LLC: OPERATING SEGMENTS
- TABLE 109.US WORLDMED, LLC: PRODUCT PORTFOLIO
- TABLE 110.US WORLDMED, LLC: NET SALES
- TABLE 111.US WORLDMED, LLC: KEY STRATERGIES
- TABLE 112.ABBVIE INC (ALLERGAN): COMPANY SNAPSHOT
- TABLE 113.ABBVIE INC (ALLERGAN): OPERATING SEGMENTS
- TABLE 114.ABBVIE INC (ALLERGAN): PRODUCT PORTFOLIO
- TABLE 115.ABBVIE INC (ALLERGAN): NET SALES
- TABLE 116.ABBVIE INC (ALLERGAN): KEY STRATERGIES
- TABLE 117.DAEWOONG PHARMACEUTICAL: COMPANY SNAPSHOT
- TABLE 118.DAEWOONG PHARMACEUTICAL: OPERATING SEGMENTS
- TABLE 119.DAEWOONG PHARMACEUTICAL: PRODUCT PORTFOLIO
- TABLE 120.DAEWOONG PHARMACEUTICAL: NET SALES
- TABLE 121.DAEWOONG PHARMACEUTICAL: KEY STRATERGIES
- TABLE 122.IPSEN GROUP: COMPANY SNAPSHOT
- TABLE 123.IPSEN GROUP: OPERATING SEGMENTS
- TABLE 124.IPSEN GROUP: PRODUCT PORTFOLIO
- TABLE 125.IPSEN GROUP: NET SALES
- TABLE 126.IPSEN GROUP: KEY STRATERGIES
- TABLE 127.MERZ PHARMA GMBH AND CO. KGAA: COMPANY SNAPSHOT
- TABLE 128.MERZ PHARMA GMBH AND CO. KGAA: OPERATING SEGMENTS
- TABLE 129.MERZ PHARMA GMBH AND CO. KGAA: PRODUCT PORTFOLIO
- TABLE 130.MERZ PHARMA GMBH AND CO. KGAA: NET SALES
- TABLE 131.MERZ PHARMA GMBH AND CO. KGAA: KEY STRATERGIES
- TABLE 132.HUGEL, INC.: COMPANY SNAPSHOT
- TABLE 133.HUGEL, INC.: OPERATING SEGMENTS
- TABLE 134.HUGEL, INC.: PRODUCT PORTFOLIO
- TABLE 135.HUGEL, INC.: NET SALES
- TABLE 136.HUGEL, INC.: KEY STRATERGIES
- TABLE 137.EVOLUS INC.: COMPANY SNAPSHOT
- TABLE 138.EVOLUS INC.: OPERATING SEGMENTS
- TABLE 139.EVOLUS INC.: PRODUCT PORTFOLIO
- TABLE 140.EVOLUS INC.: NET SALES
- TABLE 141.EVOLUS INC.: KEY STRATERGIES
- LIST OF FIGURES
- FIGURE 1.BOTULINUM TOXIN MARKET SEGMENTATION
- FIGURE 2.BOTULINUM TOXIN MARKET,2021-2031
- FIGURE 3.BOTULINUM TOXIN MARKET,2021-2031
- FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
- FIGURE 5.PORTER FIVE-1
- FIGURE 6.PORTER FIVE-2
- FIGURE 7.PORTER FIVE-3
- FIGURE 8.PORTER FIVE-4
- FIGURE 9.PORTER FIVE-5
- FIGURE 10.TOP PLAYER POSITIONING
- FIGURE 11.BOTULINUM TOXIN MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
- FIGURE 12.BOTULINUM TOXIN MARKET,BY PRODUCT,2021(%)
- FIGURE 13.COMPARATIVE SHARE ANALYSIS OF BOTULINUM TOXIN TYPE A BOTULINUM TOXIN MARKET,2021-2031(%)
- FIGURE 14.COMPARATIVE SHARE ANALYSIS OF BOTULINUM TOXIN TYPE B BOTULINUM TOXIN MARKET,2021-2031(%)
- FIGURE 15.BOTULINUM TOXIN MARKET,BY APPLICATION,2021(%)
- FIGURE 16.COMPARATIVE SHARE ANALYSIS OF AESTHETIC BOTULINUM TOXIN MARKET,2021-2031(%)
- FIGURE 17.COMPARATIVE SHARE ANALYSIS OF THERAPEUTIC BOTULINUM TOXIN MARKET,2021-2031(%)
- FIGURE 18.BOTULINUM TOXIN MARKET,BY END USER,2021(%)
- FIGURE 19.COMPARATIVE SHARE ANALYSIS OF HOSPITALS BOTULINUM TOXIN MARKET,2021-2031(%)
- FIGURE 20.COMPARATIVE SHARE ANALYSIS OF SPECIALTY AND DERMATOLOGY CLINICS BOTULINUM TOXIN MARKET,2021-2031(%)
- FIGURE 21.COMPARATIVE SHARE ANALYSIS OF OTHERS BOTULINUM TOXIN MARKET,2021-2031(%)
- FIGURE 22.BOTULINUM TOXIN MARKET BY REGION,2021
- FIGURE 23.U.S. BOTULINUM TOXIN MARKET,2021-2031($MILLION)
- FIGURE 24.CANADA BOTULINUM TOXIN MARKET,2021-2031($MILLION)
- FIGURE 25.MEXICO BOTULINUM TOXIN MARKET,2021-2031($MILLION)
- FIGURE 26.GERMANY BOTULINUM TOXIN MARKET,2021-2031($MILLION)
- FIGURE 27.FRANCE BOTULINUM TOXIN MARKET,2021-2031($MILLION)
- FIGURE 28.UK BOTULINUM TOXIN MARKET,2021-2031($MILLION)
- FIGURE 29.ITALY BOTULINUM TOXIN MARKET,2021-2031($MILLION)
- FIGURE 30.SPAIN BOTULINUM TOXIN MARKET,2021-2031($MILLION)
- FIGURE 31.REST OF EUROPE BOTULINUM TOXIN MARKET,2021-2031($MILLION)
- FIGURE 32.JAPAN BOTULINUM TOXIN MARKET,2021-2031($MILLION)
- FIGURE 33.CHINA BOTULINUM TOXIN MARKET,2021-2031($MILLION)
- FIGURE 34.AUSTRALIA BOTULINUM TOXIN MARKET,2021-2031($MILLION)
- FIGURE 35.INDIA BOTULINUM TOXIN MARKET,2021-2031($MILLION)
- FIGURE 36.SOUTH KOREA BOTULINUM TOXIN MARKET,2021-2031($MILLION)
- FIGURE 37.REST OF ASIA-PACIFIC BOTULINUM TOXIN MARKET,2021-2031($MILLION)
- FIGURE 38.BRAZIL BOTULINUM TOXIN MARKET,2021-2031($MILLION)
- FIGURE 39.SAUDI ARABIA BOTULINUM TOXIN MARKET,2021-2031($MILLION)
- FIGURE 40.SOUTH AFRICA BOTULINUM TOXIN MARKET,2021-2031($MILLION)
- FIGURE 41.REST OF LAMEA BOTULINUM TOXIN MARKET,2021-2031($MILLION)
- FIGURE 42. TOP WINNING STRATEGIES, BY YEAR
- FIGURE 43. TOP WINNING STRATEGIES, BY DEVELOPMENT
- FIGURE 44. TOP WINNING STRATEGIES, BY COMPANY
- FIGURE 45.PRODUCT MAPPING OF TOP 10 PLAYERS
- FIGURE 46.COMPETITIVE DASHBOARD
- FIGURE 47.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
- FIGURE 48.REVANCE THERAPEUTICS INC.: NET SALES ($MILLION)
- FIGURE 49.MEDY-TOX, INC..: NET SALES ($MILLION)
- FIGURE 50.GALDERMA.: NET SALES ($MILLION)
- FIGURE 51.US WORLDMED, LLC.: NET SALES ($MILLION)
- FIGURE 52.ABBVIE INC (ALLERGAN).: NET SALES ($MILLION)
- FIGURE 53.DAEWOONG PHARMACEUTICAL.: NET SALES ($MILLION)
- FIGURE 54.IPSEN GROUP.: NET SALES ($MILLION)
- FIGURE 55.MERZ PHARMA GMBH AND CO. KGAA.: NET SALES ($MILLION)
- FIGURE 56.HUGEL, INC..: NET SALES ($MILLION)
- FIGURE 57.EVOLUS INC..: NET SALES ($MILLION)
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
